Penetrium Bioscience Inc. (KOSDAQ:187660)

Market Cap	367.46B +446.5%
Revenue (ttm)	9.74B -29.3%
Net Income	-20.10B
EPS	-475.02
Shares Out	54.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,088,336
Open	6,430.00
Previous Close	6,430.00
Day's Range	6,190.00 - 7,100.00
52-Week Range	1,118.00 - 21,500.00
Beta	2.57
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2026

About Penetrium Bioscience

Penetrium Bioscience Inc., a contract research organization, provides clinical-related professional services for customer requirements in South Korea. The company offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. It also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance serv...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 160
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187660

Financial Performance

In 2024, Penetrium Bioscience's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.